Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | May 18, 2021
Finance
May 18 Quick Takes: Temasek backs Wilson, Yamada to form G2 Bio; plus PathAI, Interius, Vedere II and more
Singapore-based Temasek will supply $200 million to G2 Management Co. Inc. to foster the development of therapies from the University of Pennsylvania's Gene Therapy Program, led by James Wilson.
BioCentury | Sep 30, 2020
Product Development
Sept. 29 Quick Takes: Ironwood reduces headcount following Phase III miss; plus Sandoz, Catalyst, Myovant, Orphazyme, Synklino, WHO, BridgeBio, Kurma, Junshi, Arcutis, Genfit-LabCorp and GSK
Ironwood to downsize after Phase III GERD failureIronwood Pharmaceuticals Inc. (NASDAQ:IRWD) said it plans to discontinue development of IW-3718 after the therapy missed the primary endpoint in a
BioCentury | Aug 26, 2019
Company News
With Celgene's $13.4B sale of Otezla, Amgen adds to anti-inflammatory franchise
BioCentury | Mar 28, 2019
Product Development
Contracting practices limiting U.S. biosimilars uptake
Clinical and commercial barriers are slowing biosimilar uptake in the U.S.
BioCentury | Feb 9, 2018
Politics & Policy
American College of Rheumatology recommends biosimilars for rheumatic disease
Items per page:
1 - 10 of 14